Last reviewed · How we verify
KX-826 1.0% BID
At a glance
| Generic name | KX-826 1.0% BID |
|---|---|
| Sponsor | Suzhou Kintor Pharmaceutical Inc, |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- To Evaluate Efficacy and Safety of TopicalKX-826 Solution in Chinese Male Patients With Androgenetic Alopecia (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- KX-826 1.0% BID CI brief — competitive landscape report
- KX-826 1.0% BID updates RSS · CI watch RSS
- Suzhou Kintor Pharmaceutical Inc, portfolio CI